191 related articles for article (PubMed ID: 34503211)
1. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).
Armesto M; Marquez M; Arestin M; Errarte P; Rubio A; Manterola L; López JI; Lawrie CH
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503211
[TBL] [Abstract][Full Text] [Related]
2. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.
Aimudula A; Nasier H; Yang Y; Zhang R; Lu P; Hao J; Bao Y
Int J Clin Exp Pathol; 2018; 11(5):2389-2400. PubMed ID: 31938351
[TBL] [Abstract][Full Text] [Related]
3. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
4. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity
Ghosh S; Garige M; Haggerty PR; Norris A; Chou CK; Wu WW; Shen RF; Sourbier C
Cell Cycle; 2024 Jan; 23(1):43-55. PubMed ID: 38263737
[TBL] [Abstract][Full Text] [Related]
5. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma.
Lu L; Li Y; Wen H; Feng C
J Cancer; 2019; 10(15):3389-3396. PubMed ID: 31293642
[No Abstract] [Full Text] [Related]
7. Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma.
Li M; Zhu G; Liu Y; Li X; Zhou Y; Li C; Wang M; Zhang J; Wang Z; Tan S; Chen W; Zhang H
Heliyon; 2024 Mar; 10(6):e28295. PubMed ID: 38545181
[TBL] [Abstract][Full Text] [Related]
8. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.
Qi Y; Wang L; Wang K; Peng Z; Ma Y; Zheng Z; Shang D; Xu W; Zheng J
Biomed Pharmacother; 2019 Mar; 111():821-834. PubMed ID: 30616081
[TBL] [Abstract][Full Text] [Related]
9. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Wei Y; Chen X; Ren X; Wang B; Zhang Q; Bu H; Qian J; Shao P
Front Genet; 2021; 12():680369. PubMed ID: 34306023
[TBL] [Abstract][Full Text] [Related]
10. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Yan H; Zhang J; Lin Z
Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting stanniocalcin 2 reduces sunitinib resistance of Caki-1 renal cancer cells under hypoxia condition.
Chu H; Xie W; Guo C; Shi H; Gu J; Qin Z; Xie Y
Ann Med Surg (Lond); 2023 Dec; 85(12):5963-5971. PubMed ID: 38098599
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
14. The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma: Identification and validation of targets.
Deng Y; Wang F; Wu X; Du K; Yang Q; Xia T
Front Pharmacol; 2023; 14():1131610. PubMed ID: 37063301
[No Abstract] [Full Text] [Related]
15. Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.
Peng Q; Wang L; Zhao D; Lv Y; Wang H; Chen G; Wang J; Xu W
J Cancer; 2019; 10(5):1237-1251. PubMed ID: 30854133
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
17. Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the
Xu B; Zhu WJ; Peng YJ; Cheng SD
Transl Cancer Res; 2021 Jul; 10(7):3158-3167. PubMed ID: 35116623
[TBL] [Abstract][Full Text] [Related]
18. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
19. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
Sakaguchi T; Yoshino H; Sugita S; Miyamoto K; Yonemori M; Osako Y; Meguro-Horike M; Horike SI; Nakagawa M; Enokida H
Oncotarget; 2018 May; 9(33):23003-23017. PubMed ID: 29796168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
